Nervous System Diseases Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
- Approximately 84 eligible study participants will be randomized to either CAP-1002 or
placebo in a 1:1 ratio.
- The trial will include visits at Screening, Baseline/Day 1, Week 4, and Months 3, 6, 9,
and 12 with IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9.
- Safety evaluations will include adverse events, concomitant medications, physical exam,
vital signs, 12-lead ECG, and clinical laboratory testing.
- Efficacy will be evaluated in the Performance of the Upper Limb, pulmonary function
testing, North Star Ambulatory Assessment (ambulatory subjects only), strength testing,
cardiac MRI, and quality of life.
- If trial data suggests an appropriate risk/benefit profile of CAP-1002, Capricor, upon
the recommendation of the Data Safety Monitoring Board (DSMB), will introduce an
open-label extension study to offer CAP-1002 to study participants who were randomized
to placebo and completed all trial visits during the 12-month period.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05086809 -
Investigation of an Updated Bone-anchored Sound Processor
|
N/A | |
| Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
| Recruiting |
NCT03222375 -
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
| Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
| Completed |
NCT01922258 -
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
|
Phase 3 | |
| Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
| Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
| Completed |
NCT03994822 -
pRESET for Occlusive Stroke Treatment
|
N/A | |
| Completed |
NCT03336645 -
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
|
Phase 3 | |
| Completed |
NCT04283253 -
Predictors of Response in Chronic Stroke
|
N/A | |
| Not yet recruiting |
NCT06048523 -
Prospective Cohort Study of Neurogenetic Diseases
|
N/A | |
| Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
| Active, not recruiting |
NCT02284126 -
Topical Vancomycin for Neurosurgery Wound Prophylaxis
|
Phase 3 | |
| Completed |
NCT05815836 -
Precision Medicine in Stroke
|
||
| Completed |
NCT00739518 -
Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams
|
N/A | |
| Recruiting |
NCT03678194 -
Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application
|
N/A | |
| Recruiting |
NCT04698421 -
Collection of Biological Samples From Patients With Rare Neurological Diseases
|